Home Cart Sign in  
Chemical Structure| 54863-37-5 Chemical Structure| 54863-37-5

Structure of Dapansutrile
CAS No.: 54863-37-5

Chemical Structure| 54863-37-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

OLT1177, a β-sulfonyl nitrile molecule, is a selective inhibitor of the NLRP3 inflammasome, with unique properties to reverse the metabolic costs of inflammation and to treat IL-1β– and IL-18–mediated diseases.

Synonyms: 3-methanesulfonyl Propanenitrile; OLT1177

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dapansutrile

CAS No. :54863-37-5
Formula : C4H7NO2S
M.W : 133.17
SMILES Code : N#CCCS(=O)(C)=O
Synonyms :
3-methanesulfonyl Propanenitrile; OLT1177
MDL No. :MFCD11934305
InChI Key :LQFRYKBDZNPJSW-UHFFFAOYSA-N
Pubchem ID :12714644

Safety of Dapansutrile

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H315-H319-H332-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
human blood monocyte-derived macrophages 1 μM inhibition of IL-1β secretion Arthritis Res Ther. 2018 Aug 3;20(1):169
Mouse primary microglia cells 5 μM or 10 μM 24 h To evaluate the effect of OLT1177 on the inflammatory response of LPS-stimulated microglia. Results showed that 5 μM OLT1177 significantly reduced the release of IL-1β, IL-6, and TNF-α. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32145-32154

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Cyclophosphamide-induced interstitial cystitis model Oral gavage 100 mg/kg Every other day until the experimental endpoint on day eight Dapansutrile improved the pathology of cyclophosphamide-induced interstitial cystitis, reduced inflammation scores, decreased the frequency and number of mast cells and neutrophils, reduced T cell infiltration in the bladder, and lowered systemic proinflammatory cytokine levels. Front Immunol. 2022 Jun 3;13:903834
C57BL/6 mice Experimental autoimmune encephalomyelitis (EAE) model Oral 3.75g/kg food From the day of immunization induction, lasting for 23 days To evaluate the therapeutic effects of OLT1177 in the EAE model. Results showed that oral OLT1177 significantly improved functional deficits and spinal cord demyelination in EAE mice, and reduced protein levels of IL-1β, IL-18, IL-6, and TNF-α in the spinal cord, as well as reduced infiltration of CD4 T cells and macrophages. Front Immunol. 2019 Nov 1;10:2578
Male C57BL/6 mice Acute arthritis models (reactive arthritis and gouty arthritis) Intraperitoneal injection or oral gavage 60, 200, or 600 mg/kg 24 hours, 12 hours, and 1 hour before injection, and 11 hours and 23 hours after injection Reduced joint swelling and inflammatory cell infiltration, decreased levels of IL-1β, IL-6, and CXCL1 Arthritis Res Ther. 2018 Aug 3;20(1):169
Mice Mouse model of severe ischemic cardiomyopathy Dietary administration 3.75 g/kg and 7.5 g/kg Daily administration for 9 weeks To evaluate the protective effects of OLT1177? on contractile reserve and diastolic function after myocardial infarction. Results showed that OLT1177? significantly preserved contractile reserve and diastolic function. Molecules. 2021 Jun 9;26(12):3534

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

7.51mL

1.50mL

0.75mL

37.55mL

7.51mL

3.75mL

75.09mL

15.02mL

7.51mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories